Hims & Hers Health (NYSE:HIMS) Insider Deborah Autor Sells 16,773 Shares

Key Points

• Insider sale: Deborah Autor sold 16,773 Hims & Hers shares for approximately $467,128 under a pre-arranged Rule 10b5-1 plan, reducing her direct holdings by 25.52% to 48,961 shares.
• Mixed earnings: Quarterly revenue rose 38.2% year over year to $753.21 million, exceeding estimates, but the company reported a $0.37 loss per share versus the expected $0.05 loss.
• Analyst outlook remains cautious: Hims & Hers has a consensus “Hold” rating and an average price target of $32.43, while regulatory concerns and profitability pressure remain key risks.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Deborah Autor sold 16,773 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the transaction, the insider directly owned 48,961 shares in the company, valued at approximately $1,363,563.85. This represents a 25.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

HIMS traded up $0.86 during trading hours on Thursday, hitting $31.95. 18,861,192 shares of the stock were exchanged, compared to its average volume of 26,241,924. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40. The stock has a 50-day simple moving average of $32.17 and a 200-day simple moving average of $26.05. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. The company's quarterly revenue was up 38.2% compared to the same quarter last year. Analysts anticipate that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. State Street Corp grew its holdings in Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company's stock worth $237,210,000 after acquiring an additional 132,311 shares during the period. Geode Capital Management LLC grew its holdings in Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock worth $183,485,000 after acquiring an additional 608,950 shares during the period. Bank of America Corp DE raised its position in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company's stock worth $235,525,000 after purchasing an additional 1,600,004 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HIMS has been the subject of a number of research reports. Citigroup decreased their target price on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. UBS Group set a $23.00 price objective on Hims & Hers Health in a research note on Friday, May 22nd. Finally, Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $32.43.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source